VIA
NBIX icon

Virtus Investment Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Virtus Investment Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
7,279
+1,755
+32% +$260K 0.29% 175
2026
Q1 		$728K Buy
5,524
+1,052
+24% +$140K 0.2% 174
2025
Q4 		$634K Buy
4,472
+917
+26% +$133K 0.17% 211
2025
Q3 		$499K Hold
3,555
– – 0.14% 206
2025
Q2 		$447K Buy
3,555
+722
+25% +$82.8K 0.15% 199
2025
Q1 		$313K Sell
2,833
-1,152
-29% -$146K 0.09% 238
2024
Q4 		$544K Hold
3,985
– – 0.43% 71
2024
Q3 		$459K Hold
3,985
– – 0.36% 90
2024
Q2 		$549K Hold
3,985
– – 0.46% 65
2024
Q1 		$550K Hold
3,985
– – 0.39% 74
2023
Q4 		$525K Buy
3,985
+1,604
+67% +$185K 0.39% 73
2023
Q3 		$268K Buy
+2,381
New +$251K 0.18% 137

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtus Investment Advisers's NBIX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Neurocrine Biosciences (NBIX) stake by 32% in Q2 2026, buying an estimated $260K and bringing the position to 7,279 shares worth $1.23M. The position accounts for 0.29% of the portfolio, ranked #175.

Virtus Investment Advisers first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Virtus Investment Advisers held 7,279 shares of Neurocrine Biosciences worth $1.23M as of Q2 2026.
  • Virtus Investment Advisers bought 1,755 Neurocrine Biosciences shares in Q2 2026, an estimated $260K.
  • Neurocrine Biosciences made up 0.29% of Virtus Investment Advisers's portfolio in Q2 2026, its #175 holding.
  • Virtus Investment Advisers first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.